Abstract
The origin of vascular smooth muscle cells that accumulate in the neointima in vascular diseases such as transplant arteriosclerosis, atherosclerosis and restenosis remains subject to much debate. Smooth muscle cells are a highly heterogeneous cell population with different characteristics and markers, and distinct phenotypes in physiological and pathological conditions. Several studies have reported a role for bone marrow-derived progenitor cells in vascular maintenance and repair. Moreover, bone marrow-derived smooth muscle progenitor cells have been detected in human atherosclerotic tissue as well as in in vivo mouse models of vascular disease. However, it is not clear whether smooth muscle progenitor cells can be regarded as a ‘friend’ or ‘foe’ in neointima formation. In this review we will discuss the heterogeneity of smooth muscle cells, the role of smooth muscle progenitor cells in vascular disease, potential mechanisms that could regulate smooth muscle progenitor cell contribution and the implications this may have on designing novel therapeutic tools to prevent development and progression of vascular disease.
Keywords: Smooth muscle progenitor cells, bone marrow, vascular disease
Current Stem Cell Research & Therapy
Title: Smooth Muscle Progenitor Cells: Friend or Foe in Vascular Disease?
Volume: 4 Issue: 2
Author(s): Olivia van Oostrom, Joost O. Fledderus, Dominique de Kleijn, Gerard Pasterkamp and Marianne C. Verhaar
Affiliation:
Keywords: Smooth muscle progenitor cells, bone marrow, vascular disease
Abstract: The origin of vascular smooth muscle cells that accumulate in the neointima in vascular diseases such as transplant arteriosclerosis, atherosclerosis and restenosis remains subject to much debate. Smooth muscle cells are a highly heterogeneous cell population with different characteristics and markers, and distinct phenotypes in physiological and pathological conditions. Several studies have reported a role for bone marrow-derived progenitor cells in vascular maintenance and repair. Moreover, bone marrow-derived smooth muscle progenitor cells have been detected in human atherosclerotic tissue as well as in in vivo mouse models of vascular disease. However, it is not clear whether smooth muscle progenitor cells can be regarded as a ‘friend’ or ‘foe’ in neointima formation. In this review we will discuss the heterogeneity of smooth muscle cells, the role of smooth muscle progenitor cells in vascular disease, potential mechanisms that could regulate smooth muscle progenitor cell contribution and the implications this may have on designing novel therapeutic tools to prevent development and progression of vascular disease.
Export Options
About this article
Cite this article as:
Oostrom van Olivia, Fledderus O. Joost, de Kleijn Dominique, Pasterkamp Gerard and Verhaar C. Marianne, Smooth Muscle Progenitor Cells: Friend or Foe in Vascular Disease?, Current Stem Cell Research & Therapy 2009; 4 (2) . https://dx.doi.org/10.2174/157488809788167454
DOI https://dx.doi.org/10.2174/157488809788167454 |
Print ISSN 1574-888X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3946 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Leptin and the Cardiovascular System: A Review
Recent Patents on Cardiovascular Drug Discovery Ezetimibe and Vascular Inflammation
Current Vascular Pharmacology Gene-environment Interactions in Late Life: Linking Psychosocial Stress with Brain Aging
Current Neuropharmacology Sodium Intake, Circulating Microvesicles and Cardiovascular Outcomes in Type 2 Diabetes
Current Diabetes Reviews ALA, Fatty Fish or Marine n-3 Fatty Acids for Preventing DM?: A Systematic Review and Meta-Analysis
Current Diabetes Reviews Cellular Senescence in Cardiovascular Diseases: Potential Age-Related Mechanisms and Implications for Treatment
Current Pharmaceutical Design PEDF & Stem Cells: Niche vs. Nurture
Current Drug Delivery Reactive Oxygen Species in Myocardial Reperfusion Injury: From Physiopathology to Therapeutic Approaches
Current Pharmaceutical Biotechnology Elevated Levels of Soluble Fibrin in Patients with Thrombosis or a Pre- Thrombotic State
Vascular Disease Prevention (Discontinued) Subject Index to Volume 4
Current Genomics Ageing Mechanisms and Associated Lipid Changes
Current Vascular Pharmacology Diabetes and Antioxidants: Myth or Reality?
Current Vascular Pharmacology Discovery of Anticoagulant Drugs: A Historical Perspective
Current Drug Discovery Technologies Role of Heme Oxygenase-1 in Cardiovascular Function
Current Pharmaceutical Design Dyslipidemia, Metabolic Syndrome and Vascular Disease Among Asian Indians
Vascular Disease Prevention (Discontinued) Targeting JAK/STAT Signaling Pathway in Inflammatory Diseases
Current Signal Transduction Therapy Genomic Variations Affecting Biological Effects of Statins
Current Drug Metabolism Contemporary Review of Drugs Used to Treat Obesity
Cardiovascular & Hematological Agents in Medicinal Chemistry Fetal Programming of the Human Brain: Is there a Link with Insurgence of Neurodegenerative Disorders in Adulthood?
Current Medicinal Chemistry New Patents on Topical Anesthetics
Recent Patents on Inflammation & Allergy Drug Discovery